Want to see DE:CHG full AI Analyst Report?
Top Page
MEDIQON Group AG
(XETRA:CHG)
Select Model
Select Model
Rating:43Neutral
Price Target:
€41.00
▼(-0.85% Downside)
Action:Reiterated
Date:10/01/26
The score is pressured primarily by weak financial performance—especially the 2025 profitability collapse and sharply higher debt—despite continued strong revenue growth and positive free cash flow. Technical indicators also point to a bearish trend, with oversold signals not yet supported by improving momentum. Valuation is constrained by losses (negative P/E) and no provided dividend yield.
Positive Factors
Strong Revenue Growth
Rapid revenue expansion indicates strong demand for the company’s healthcare and life sciences services and solutions. Continued top-line growth can broaden market reach and create operating leverage, provided management can convert scale into sustainable profitability.
Negative Factors
Severe Profitability Deterioration
The sharp reversal from a more normal 2024 gross-profit level shows that revenue growth is not currently translating into earnings. Large operating and net losses weaken retained capital, constrain reinvestment, and make sustainable profitability a central execution challenge.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Rapid revenue expansion indicates strong demand for the company’s healthcare and life sciences services and solutions. Continued top-line growth can broaden market reach and create operating leverage, provided management can convert scale into sustainable profitability.
Read all positive factors
MEDIQON Group AG (CHG) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.07B
Dividend YieldN/A
Average Volume (3M)29.73K
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue Growth63.32%
EPS Growth-47.16%
CountryDE
Employees1,300
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)-1.26
Shares Outstanding25,364,090
10 Day Avg. Volume20,643
30 Day Avg. Volume29,735
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)4.42
Price to Sales (P/S)5.47
P/FCF Ratio140.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)€238.13M
MEDIQON Group AG Business Overview & Revenue Model
Company Description
CHAPTERS Group AG, headquartered in Hamburg, Germany, was established in 1998 and rebranded from MEDIQON Group AG in July 2023. The company delivers a broad spectrum of software solutions across the DACH region, catering to numerous industries and...
MEDIQON Group AG Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
46
Neutral
Cash Flow
57
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2021 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 180.80M | 110.67M | 70.77M | 42.07M | 28.66M |
| Gross Profit | -12.21M | 47.02M | 8.38M | 6.84M | 12.26M |
| EBITDA | -2.40M | 16.35M | 16.14M | 4.82M | 7.16M |
| Net Income | -29.65M | -11.47M | -4.08M | -5.88M | -2.27M |
Balance Sheet | |||||
| Total Assets | 665.02M | 353.74M | 223.95M | 169.28M | 103.55M |
| Cash, Cash Equivalents and Short-Term Investments | 106.74M | 58.51M | 50.84M | 26.28M | 11.09M |
| Total Debt | 247.94M | 73.60M | 69.35M | 62.09M | 51.70M |
| Total Liabilities | 351.45M | 128.75M | 99.87M | 77.11M | 61.71M |
| Stockholders Equity | 223.87M | 224.99M | 126.06M | 93.76M | 42.57M |
Cash Flow | |||||
| Free Cash Flow | 7.02M | 6.96M | 3.81M | 3.67M | 1.15M |
| Operating Cash Flow | 8.68M | 11.47M | 7.37M | 5.69M | 2.87M |
| Investing Cash Flow | -103.89M | -98.82M | -36.34M | -53.21M | -47.40M |
| Financing Cash Flow | 134.24M | 89.00M | 48.15M | 58.78M | 47.06M |
MEDIQON Group AG Technical Analysis
Positive
41.35
Price Trends
43.76
Negative
39.98
Positive
36.44
Positive
Market Momentum
-0.74
Negative
49.96
Neutral
85.44
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:CHG, the sentiment is Positive. The current price of 41.35 is below the 20-day moving average (MA) of 41.37, below the 50-day MA of 43.76, and above the 200-day MA of 36.44, indicating a neutral trend. The MACD of -0.74 indicates Negative momentum. The RSI at 49.96 is Neutral, neither overbought nor oversold. The STOCH value of 85.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:CHG.
MEDIQON Group AG Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €44.13M | 11.65 | 10.52% | 2.15% | 0.88% | 9.19% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
60 Neutral | €4.39B | 17.80 | 12.00% | 2.01% | 7.74% | 14.82% | |
59 Neutral | €418.46M | 22.57 | 9.65% | 1.22% | 12.73% | 51.34% | |
54 Neutral | €353.72M | -35.32 | -8.99% | 1.69% | -1.94% | -161.38% | |
43 Neutral | €1.07B | -33.33 | -13.21% | ― | 63.32% | -47.16% |
* Technology Sector Average
DE:CHG
MEDIQON Group AG
42.00
5.40
14.75%
DE:ADN1
adesso AG
64.10
-33.42
-34.27%
DE:A1OS
All for One Group
71.00
29.65
71.69%
DE:BC8
Bechtle Aktiengesellschaft
34.88
0.15
0.43%
DE:AMI
medondo holding AG
0.18
-0.33
-64.47%
DE:OBS
ORBIS AG
4.66
-0.97
-17.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.